Interaction of vanadium(IV) with human serum apo-transferrin.

[1]  G. Micera,et al.  Transport of the anti-diabetic VO2+ complexes formed by pyrone derivatives in the blood serum. , 2012, Journal of inorganic biochemistry.

[2]  P. López-Larrubia,et al.  VO(dmpp)2 normalizes pre-diabetic parameters as assessed by in vivo magnetic resonance imaging and spectroscopy. , 2012, Journal of inorganic biochemistry.

[3]  B. Barisas,et al.  The anti-diabetic bis(maltolato)oxovanadium(IV) decreases lipid order while increasing insulin receptor localization in membrane microdomains. , 2012, Dalton transactions.

[4]  Xiaole Kong,et al.  Iron mobilization from transferrin by therapeutic iron chelating agents. , 2012, Biochimica et biophysica acta.

[5]  G. Micera,et al.  Coordinating Properties of Pyrone and Pyridinone Derivatives, Tropolone and Catechol toward the VO2+ Ion: An Experimental and Computational Approach , 2012 .

[6]  G. Micera,et al.  Biotransformation of BMOV in the presence of blood serum proteins. , 2012, Metallomics : integrated biometal science.

[7]  P. A. Lay,et al.  Metal-based anti-diabetic drugs: advances and challenges. , 2011, Dalton transactions.

[8]  T. Kiss,et al.  The speciation of vanadium in human serum , 2011 .

[9]  Zihua Hu,et al.  Anti-diabetic effects of a series of vanadium dipicolinate complexes in rats with streptozotocin-induced diabetes. , 2011, Coordination chemistry reviews.

[10]  D. Gambino.  Potentiality of vanadium compounds as anti-parasitic agents , 2011 .

[11]  G. Micera,et al.  Interaction of VO2+ ion and some insulin-enhancing compounds with immunoglobulin G. , 2011, Inorganic chemistry.

[12]  V. Moreno,et al.  Vanadium polypyridyl compounds as potential antiparasitic and antitumoral agents: new achievements. , 2011, Journal of inorganic biochemistry.

[13]  R. K. Marcus,et al.  Instrumental comparison of the determination of Cr³+ uptake by human transferrin. , 2010, Metallomics : integrated biometal science.

[14]  J. Pessoa,et al.  Transport of therapeutic vanadium and ruthenium complexes by blood plasma components. , 2010, Current medicinal chemistry.

[15]  H. Sakurai,et al.  Metallo-allixinate complexes with anti-diabetic and anti-metabolic syndrome activities. , 2010, Metallomics : integrated biometal science.

[16]  H. Faneca,et al.  Study of the antidiabetic capacity of the VO(dmpp)2 complex. , 2010, Journal of inorganic biochemistry.

[17]  G. Micera,et al.  A quantitative study of the biotransformation of insulin-enhancing VO2+ compounds , 2010, JBIC Journal of Biological Inorganic Chemistry.

[18]  R. K. Marcus,et al.  Simultaneous multiple element detection by particle beam/hollow cathode-optical emission spectroscopy as a tool for metallomic studies: determinations of metal binding with apo-transferrin. , 2010, Metallomics : integrated biometal science.

[19]  N. Mondal,et al.  Vanadium complexes having [V(IV)O](2+) and [V(V)O(2)](+) cores with binucleating dibasic tetradentate ligands: Synthesis, characterization, catalytic and antiamoebic activities. , 2010, Dalton transactions.

[20]  T. Kiss,et al.  Vanadate complexes in serum: a speciation modeling study. , 2010, Dalton transactions.

[21]  G. Micera,et al.  New developments in the comprehension of the biotransformation and transport of insulin-enhancing vanadium compounds in the blood serum. , 2010, Inorganic chemistry.

[22]  F. Avilés,et al.  A novel vanadyl complex with a polypyridyl DNA intercalator as ligand: a potential anti-protozoa and anti-tumor agent. , 2009, Journal of inorganic biochemistry.

[23]  Erin E. Battin,et al.  Using Proteins in a Bioinorganic Laboratory Experiment: Iron Loading and Removal from Transferrin , 2009 .

[24]  G. Micera,et al.  On the transport of vanadium in blood serum. , 2009, Inorganic chemistry.

[25]  H. Sakurai,et al.  Novel 3-hydroxy-4-pyridinonato oxidovanadium(IV) complexes to investigate structure/activity relationships. , 2009, Journal of inorganic biochemistry.

[26]  G. Micera,et al.  Interaction of VO2+ ion with human serum transferrin and albumin. , 2009, Journal of inorganic biochemistry.

[27]  C. Haynes,et al.  Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin. , 2009, Journal of inorganic biochemistry.

[28]  J. McNeill,et al.  Vanadium treatment of type 2 diabetes: a view to the future. , 2009, Journal of inorganic biochemistry.

[29]  C. Geraldes,et al.  Vanadium compounds as therapeutic agents: some chemical and biochemical studies. , 2009, Journal of inorganic biochemistry.

[30]  A. Mason,et al.  Human serum transferrin: a tale of two lobes. Urea gel and steady state fluorescence analysis of recombinant transferrins as a function of pH, time, and the soluble portion of the transferrin receptor , 2009, JBIC Journal of Biological Inorganic Chemistry.

[31]  A. Sanz-Medel,et al.  Biospeciation of various antidiabetic V(IV)O compounds in serum. , 2009, Dalton transactions.

[32]  H. Sakurai,et al.  Biospeciation of antidiabetic VO(IV) complexes , 2008 .

[33]  Yusuke Adachi,et al.  Action mechanism of bis(allixinato)oxovanadium(IV) as a novel potent insulin-mimetic complex: regulation of GLUT4 translocation and FoxO1 transcription factor , 2007, JBIC Journal of Biological Inorganic Chemistry.

[34]  Katherine H Thompson,et al.  Vanadium in diabetes: 100 years from Phase 0 to Phase I. , 2006, Journal of inorganic biochemistry.

[35]  Hiromu Sakurai,et al.  Chemistry and Biochemistry of Insulin-Mimetic Vanadium and Zinc Complexes. Trial for Treatment of Diabetes Mellitus , 2006 .

[36]  G. Micera,et al.  Spectroscopic and potentiometric characterization of oxovanadium(IV) complexes formed by 3-hydroxy-4-pyridinones. Rationalization of the influence of basicity and electronic structure of the ligand on the properties of V(IV)O species in aqueous solution. , 2006, Inorganic chemistry.

[37]  H. Sakurai,et al.  Binding constant of VIVO to transferrin , 2006 .

[38]  A. Gorzsás,et al.  On the Fate of Vanadate in Human Blood , 2006 .

[39]  Y. Adachi,et al.  Possible mode of action for insulinomimetic activity of vanadyl(IV) compounds in adipocytes. , 2006, Life sciences.

[40]  M. Jakupec,et al.  From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). , 2006, Journal of inorganic biochemistry.

[41]  Katherine H Thompson,et al.  Metal complexes in medicinal chemistry: new vistas and challenges in drug design. , 2006, Dalton transactions.

[42]  C. Geraldes,et al.  Uptake and metabolic effects of insulin mimetic oxovanadium compounds in human erythrocytes. , 2005, Journal of inorganic biochemistry.

[43]  G. Willsky,et al.  Aqueous chemistry of the vanadium(III) (V(III)) and the V(III)-dipicolinate systems and a comparison of the effect of three oxidation states of vanadium compounds on diabetic hyperglycemia in rats. , 2005, Inorganic chemistry.

[44]  Edmond Lam,et al.  New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals. , 2005, Journal of the American Chemical Society.

[45]  E. Castellano,et al.  Vanadium(V) complexes with salicylaldehyde semicarbazone derivatives bearing in vitro anti-tumor activity toward kidney tumor cells (TK-10): crystal structure of [VVO2(5-bromosalicylaldehyde semicarbazone)]. , 2005, Journal of inorganic biochemistry.

[46]  H. Akiyama,et al.  Binding patterns of vanadium to transferrin in healthy human serum studied with HPLC/high resolution ICP-MS. , 2004, The Analyst.

[47]  K. Raymond,et al.  Large cooperativity in the removal of iron from transferrin at physiological temperature and chloride ion concentration , 2004, JBIC Journal of Biological Inorganic Chemistry.

[48]  A. Evangelou,et al.  Solid state and solution studies of a vanadium(III)-L-cysteine compound and demonstration of its antimetastatic, antioxidant and inhibition of neutral endopeptidase activities. , 2004, Journal of inorganic biochemistry.

[49]  H. Sakurai,et al.  Pharmacokinetic study and trial for preparation of enteric-coated capsule containing insulinomimetic vanadyl compounds: implications for clinical use. , 2003, Mini reviews in medicinal chemistry.

[50]  Michael D. Johnson,et al.  Vanadium(IV) and vanadium(V) complexes of dipicolinic acid and derivatives. Synthesis, X-ray structure, solution state properties: and effects in rats with STZ-induced diabetes , 2003 .

[51]  Michael G. Davis,et al.  Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component. , 2003, Journal of inorganic biochemistry.

[52]  Y. Adachi,et al.  The therapeutic potential of insulin-mimetic vanadium complexes , 2003, Expert opinion on investigational drugs.

[53]  F. Uckun,et al.  Metvan: a novel oxovanadium(IV) complex with broad spectrum anticancer activity , 2002, Expert opinion on investigational drugs.

[54]  R. Hider,et al.  Design of iron chelators with therapeutic application , 2002 .

[55]  T. Maitani,et al.  Binding patterns of vanadium ions with different valence states to human serum transferrin studied by HPLC/high-resolution ICP-MS. , 2002, Biochemical and biophysical research communications.

[56]  H. Sakurai.  A new concept: the use of vanadium complexes in the treatment of diabetes mellitus. , 2002, Chemical record.

[57]  R. Vanholder,et al.  Fractionation of vanadium complexes in serum, packed cells and tissues of Wistar rats by means of gel filtration and anion-exchange chromatography , 2002, JBIC Journal of Biological Inorganic Chemistry.

[58]  A. Evangelou.  Vanadium in cancer treatment. , 2002, Critical reviews in oncology/hematology.

[59]  A. Salifoglou,et al.  In vitro study of the insulin-mimetic behaviour of vanadium(IV, V) coordination compounds , 2002, JBIC Journal of Biological Inorganic Chemistry.

[60]  Hiromu Sakurai,et al.  Antidiabetic vanadium(IV) and zinc(II) complexes , 2002 .

[61]  H. Sakurai,et al.  In vitro study of the insulin-like action of vanadyl-pyrone and -pyridinone complexes with a VO(O4) coordination mode , 2001, JBIC Journal of Biological Inorganic Chemistry.

[62]  H. Sakurai,et al.  Speciation of insulin-mimetic VO(IV)-containing drugs in blood serum. , 2000, Journal of inorganic biochemistry.

[63]  L. Brunel,et al.  High-Frequency Electron Paramagnetic Resonance Studies of VO2+ in Low-Temperature Glasses , 1999 .

[64]  K. Fukui,et al.  In vivo coordination structural changes of a potent insulin-mimetic agent, bis(picolinato)oxovanadium(IV), studied by electron spin-echo envelope modulation spectroscopy. , 1999, Journal of inorganic biochemistry.

[65]  P J Sadler,et al.  Transferrin as a metal ion mediator. , 1999, Chemical reviews.

[66]  M. Battell,et al.  Vanadium compounds as insulin mimics. , 1999, Metal ions in biological systems.

[67]  J. McNeill,et al.  Vanadium Complexes as Insulin Mimetic Agents: Coordination Chemistry and in Vivo Studies of Oxovanadium(IV) and Dioxovanadate(V) Complexes Formed from Naturally Occurring Chelating Oxazolinate, Thiazolinate, or Picolinate Units† , 1999 .

[68]  G. Micera,et al.  The formation of ternary complexes between VO(maltolate)2 and small bioligands , 1998 .

[69]  G. Hanson,et al.  Characterization of the Potent Insulin Mimetic Agent Bis(maltolato)oxovanadium(IV) (BMOV) in Solution by EPR Spectroscopy. , 1996, Inorganic chemistry.

[70]  E. Baker,et al.  Binding of ruthenium(III) anti-tumor drugs to human lactoferrin probed by high resolution X-ray crystallographic structure analyses , 1996, JBIC Journal of Biological Inorganic Chemistry.

[71]  F. G. Herring,et al.  Reaction chemistry of BMOV, bis(maltolato)oxovanadium(IV), a potent insulin mimetic agent , 1995 .

[72]  Shuang Liu,et al.  Potentiometric, Calorimetric, and Solution NMR Studies of a Tridentate Ligand Which has a Marked Preference for Formation of Bis(ligand) versus Mono(ligand) Lanthanide Complexes and Which Exhibits High Selectivity for Heavier Lanthanides , 1995 .

[73]  P. Sadler,et al.  pH-induced structural changes in human serum apotransferrin. pKa values of histidine residues and N-terminal amino group determined by 1H-NMR spectroscopy. , 1994, European journal of biochemistry.

[74]  L. Messori,et al.  The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. , 1994, The Journal of biological chemistry.

[75]  A. Martell,et al.  Stabilities of 1,2-dimethyl-3-hydroxy-4-pyridinone chelates of divalent and trivalent metal ions , 1992 .

[76]  J. Meyerovitch,et al.  Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action. , 1987, The Journal of biological chemistry.

[77]  J. K. Grady,et al.  Characterization of the binding, kinetics, and redox stability of vanadium(IV) and vanadium(V) protein complexes in serum , 1986 .

[78]  W. R. Harris,et al.  Thermodynamics of anion binding to human serum transferrin. , 1985, Biochemistry.

[79]  J. McNeill,et al.  Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. , 1985, Science.

[80]  J. Williams,et al.  The distribution of iron between the metal-binding sites of transferrin human serum. , 1980, The Biochemical journal.

[81]  R. W. Evans,et al.  Studies of the binding of different iron donors to human serum transferrin and isolation of iron-binding fragments from the N- and C-terminal regions of the protein. , 1978, The Biochemical journal.

[82]  P. Aisen,et al.  Stoichiometric and site characteristics of the binding of iron to human transferrin. , 1978, The Journal of biological chemistry.

[83]  D. C. Harris.  Different metal-binding properties of the two sites of human transferrin. , 1977, Biochemistry.

[84]  Chasteen Nd,et al.  Nonequivalence of the metal binding sites in vanadyl-labeled human serum transferrin. , 1975, Biochemistry.

[85]  Farrington Daniels,et al.  Physical Chemistry, 2nd Ed. , 1961 .

[86]  M. Hiromura,et al.  Glucose lowering activity by oral administration of bis(allixinato)oxidovanadium(IV) complex in streptozotocin-induced diabetic mice and gene expression profiling in their skeletal muscles , 2009 .

[87]  D. Rehder.  Bioinorganic Vanadium Chemistry , 2008 .

[88]  S. Bhanot,et al.  Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential , 2002, JBIC Journal of Biological Inorganic Chemistry.

[89]  C. Orvig,et al.  Design of vanadium compounds as insulin enhancing agents , 2000 .

[90]  P. Sadler,et al.  Rationalisation of metal binding to transferrin: Prediction of metal-protein stability constants , 1997 .

[91]  N. Durai,et al.  Insulin-Like Effects of Bis-Salicylidine Ethylenediiminato Oxovanadium (IV) Complex on Carbohydrate Metabolism , 1997 .

[92]  J. Libman,et al.  The Coordination of VO2+ to Hydroxamate Binders as Studied by Orientation Selective ESEEM Spectroscopy , 1995 .

[93]  E. Baker,et al.  Protein-binding Properties of two Antitumour Ru(III) Complexes to Human Apotransferrin and Apolactoferrin , 1994, Metal-based drugs.

[94]  N. Chasteen,et al.  A Q-band electron paramagnetic resonance study of vanadyl(IV)-labeled human serotransferrin , 1979 .

[95]  N. Chasteen.  Human serotransferrin: structure and function , 1977 .